GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vitrolife AB (LTS:0YAY) » Definitions » COGS-to-Revenue

Vitrolife AB (LTS:0YAY) COGS-to-Revenue : 0.43 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Vitrolife AB COGS-to-Revenue?

Vitrolife AB's Cost of Goods Sold for the three months ended in Mar. 2025 was kr359 Mil. Its Revenue for the three months ended in Mar. 2025 was kr842 Mil.

Vitrolife AB's COGS to Revenue for the three months ended in Mar. 2025 was 0.43.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Vitrolife AB's Gross Margin % for the three months ended in Mar. 2025 was 57.36%.


Vitrolife AB COGS-to-Revenue Historical Data

The historical data trend for Vitrolife AB's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vitrolife AB COGS-to-Revenue Chart

Vitrolife AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 0.38 0.45 0.44 0.41

Vitrolife AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.40 0.41 0.39 0.43

Vitrolife AB COGS-to-Revenue Calculation

Vitrolife AB's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1470 / 3609
=0.41

Vitrolife AB's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=359 / 842
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vitrolife AB  (LTS:0YAY) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Vitrolife AB's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 359 / 842
=57.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Vitrolife AB COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vitrolife AB's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Vitrolife AB Business Description

Traded in Other Exchanges
Address
Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The group has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.

Vitrolife AB Headlines

No Headlines